发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
Shire: a specialty global biopharmaceutical company 夏尔:一家专业的全球生物制药公司
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.51
{"title":"Shire: a specialty global biopharmaceutical company","authors":"","doi":"10.1002/fps.51","DOIUrl":"https://doi.org/10.1002/fps.51","url":null,"abstract":"<p>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Shire and its current portfolio, and look at its current pipeline and areas of research interest. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137672895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agomelatine: a new treatment for depression 阿戈美拉汀:一种治疗抑郁症的新方法
Future Prescriber Pub Date : 2009-04-28 DOI: 10.1002/fps.48
Professor Bill Deakin
{"title":"Agomelatine: a new treatment for depression","authors":"Professor Bill Deakin","doi":"10.1002/fps.48","DOIUrl":"10.1002/fps.48","url":null,"abstract":"<p>It is estimated that depression carries the greatest burden of disability in established economies. A range of treatments are available, and selective serotonin reuptake inhibitors (SSRIs) are currently the most commonly prescribed class of antidepressant. In this article, the author discusses agomelatine, a novel antidepressant recently licensed by the European Medicines Agency (EMEA), the evidence for its use, and its potential place in therapy. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"14-19"},"PeriodicalIF":0.0,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82195361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Gefitinib - a potential new treatment option in lung cancer 吉非替尼-一个潜在的治疗肺癌的新选择
Future Prescriber Pub Date : 2009-04-28 DOI: 10.1002/fps.47
Dr Fiona Blackhall, Steve Chaplin
{"title":"Gefitinib - a potential new treatment option in lung cancer","authors":"Dr Fiona Blackhall,&nbsp;Steve Chaplin","doi":"10.1002/fps.47","DOIUrl":"10.1002/fps.47","url":null,"abstract":"<p>Lung cancer is the second most common cancer in the UK, accounting for one in seven new cases, 24% of cancer deaths among men and 20% among women.<sup>1</sup> In this article, Dr Fiona Blackhall and Steve Chaplin consider the use of gefitinib for lung cancer its mechanism of action, efficacy and adverse effects are described, followed by its effect on quality of life and its potential place in disease management. Pharmacist Geoff Saunders provides a commentary on the article and remarks on the selective use of gefitinib in lung cancer therapy. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"7-13"},"PeriodicalIF":0.0,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.47","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82972033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High-cost drugs – the Welsh perspective 高价药品——威尔士人的观点
Future Prescriber Pub Date : 2009-04-28 DOI: 10.1002/fps.46
Dr Martin Duerden
{"title":"High-cost drugs – the Welsh perspective","authors":"Dr Martin Duerden","doi":"10.1002/fps.46","DOIUrl":"10.1002/fps.46","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.46","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85394655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dronedarone: a new option in atrial fibrillation Dronedarone:房颤治疗的新选择
Future Prescriber Pub Date : 2009-02-26 DOI: 10.1002/fps.45
Professor A. John Camm MD, Irina Savelieva MD
{"title":"Dronedarone: a new option in atrial fibrillation","authors":"Professor A. John Camm MD,&nbsp;Irina Savelieva MD","doi":"10.1002/fps.45","DOIUrl":"10.1002/fps.45","url":null,"abstract":"<p>Many antiarrhythmic agents exploiting new mechanisms of action (as well as modified analogues of traditional antiarrhythmic drugs, with different combinations of ion channel- and receptor-blocking effects and less complicated metabolic profiles) are currently being investigated. Dronedarone is an amiodarone derivative that is devoid of iodine atoms and is believed to have a better safety profile than amiodarone. It is the only antiarrhythmic drug for the treatment of atrial fibrillation (AF) that has been shown to improve survival in high-risk patients. This review provides a contemporary insight into the clinical development of dronedarone, its efficacy and safety in preventing recurrent AF, and its potential additional advantage of improving outcome in patients with AF. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"24-32"},"PeriodicalIF":0.0,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.45","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78425453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nicotinic acid/laropiprant: a new lipid-modifying therapy 烟酸/laropiprant:一种新的脂质调节疗法
Future Prescriber Pub Date : 2009-02-26 DOI: 10.1002/fps.44
Steve Chaplin MSc, MRPharmS, Marc Evans MRCP, MD
{"title":"Nicotinic acid/laropiprant: a new lipid-modifying therapy","authors":"Steve Chaplin MSc, MRPharmS,&nbsp;Marc Evans MRCP, MD","doi":"10.1002/fps.44","DOIUrl":"10.1002/fps.44","url":null,"abstract":"<p>Cardiovascular disease (CVD) is a leading cause of death in the UK.<sup>1</sup> Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid-modifying therapy, a modified-release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82926086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tocilizumab — IL-6 inhibition for the treatment of rheumatoid arthritis Tocilizumab - IL-6抑制治疗类风湿关节炎
Future Prescriber Pub Date : 2009-02-26 DOI: 10.1002/fps.41
Professor Paul Emery MA, MD, FRCP, Rhonda Siddall
{"title":"Tocilizumab — IL-6 inhibition for the treatment of rheumatoid arthritis","authors":"Professor Paul Emery MA, MD, FRCP,&nbsp;Rhonda Siddall","doi":"10.1002/fps.41","DOIUrl":"10.1002/fps.41","url":null,"abstract":"<p>Affecting approximately 400 000 people in England and Wales,<sup>1</sup> rheumatoid arthritis (RA) creates a considerable economic burden. NICE estimates that five years after diagnosis, 40% of RA patients will be incapable of work.<sup>1</sup> Some treatment options for RA look to control inflammation in order to rein in the disease. Interleukin-6 (IL-6) invokes inflammation via TNF-α, although the reason for this is unknown. Some researchers are beginning to turn their attention to IL-6 in their search for novel RA treatments, and believe that drugs inhibiting this inflammatory cytokine could halt disease progression. In this article, we consider tocilizumab, an IL-6 inhibitor. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73490220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Degarelix: a new hormonal treatment for prostate cancer Degarelix:一种治疗前列腺癌的新激素
Future Prescriber Pub Date : 2009-02-26 DOI: 10.1002/fps.42
Professor Malcolm Mason
{"title":"Degarelix: a new hormonal treatment for prostate cancer","authors":"Professor Malcolm Mason","doi":"10.1002/fps.42","DOIUrl":"10.1002/fps.42","url":null,"abstract":"<p>According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.<sup>1</sup> The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"11-15"},"PeriodicalIF":0.0,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.42","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76775226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Prolonged-release oxycodone/naloxone for chronic pain 缓释羟考酮/纳洛酮治疗慢性疼痛
Future Prescriber Pub Date : 2009-02-26 DOI: 10.1002/fps.43
Nicola O'Connell, Karen H Simpson FRCA, FFPMRCA
{"title":"Prolonged-release oxycodone/naloxone for chronic pain","authors":"Nicola O'Connell,&nbsp;Karen H Simpson FRCA, FFPMRCA","doi":"10.1002/fps.43","DOIUrl":"10.1002/fps.43","url":null,"abstract":"<p>Chronic pain is common, and opioid therapy is often required for pain management. Unfortunately, opioid-induced bowel dysfunction (OIBD) is a frequent and debilitating side-effect of opioid use. A new prolonged-release (PR) preparation of oxycodone/naloxone has been developed for moderate-to-severe pain that reduces OIBD in patients. In this article, we consider the mode of action and efficacy of this combination opioid therapy for chronic pain. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"16-19"},"PeriodicalIF":0.0,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.43","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72745921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Shingles vaccine: prevention made possible 带状疱疹疫苗:预防成为可能
Future Prescriber Pub Date : 2009-01-19 DOI: 10.1002/fps.40
Sue Lyon
{"title":"Shingles vaccine: prevention made possible","authors":"Sue Lyon","doi":"10.1002/fps.40","DOIUrl":"10.1002/fps.40","url":null,"abstract":"<p>Pain specialists discuss the key issues around vaccination against shingles and postherpetic neuralgia (PHN) at the Sanofi Pasteur MSD-sponsored Satellite Symposium at the British Pain Society Meeting, Liverpool. Copyright © 2008 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"25-27"},"PeriodicalIF":0.0,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.40","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"112496806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信